Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. - Wikidata - awgldk - TriplyDB

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.

http://www.wikidata.org/entity/Q33406648

about

Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.Immune thrombocytopenia in chronic myelomonocytic leukemia.Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.Integrated analysis of germline and somatic variants in ovarian cancer.Clinical and genetic predictors of prognosis in myelodysplastic syndromes.CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia.Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.Digging deep into "dirty" drugs - modulation of the methylation machinery.Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Chronic myelomonocytic leukemia: Forefront of the field in 2015.ASXL1 plays an important role in erythropoiesis.TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia.Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.Age-related mutations and chronic myelomonocytic leukemia.Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy.Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.CMML: Clinical and molecular aspects.ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival.Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.Bone Marrow Conventional Karyotyping and Fluorescence In Situ Hybridization: Defining an Effective Utilization Strategy for Evaluation of Myelodysplastic Syndromes.An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.Genetic stratification in myeloid diseases: from risk assessment to clinical decision support tool.Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.

P2860

Q26752940-712FEE63-0A6D-4928-BC94-2539B5BEFB41 Q26768600-45AACB1B-1022-44DE-815D-99652620D99B Q30274942-140C4E3D-FB8C-4631-91FE-E34D26670541 Q33415834-4166461C-49FF-42BA-85D4-1112445D69E9 Q33600822-11A75799-E2FB-4FBE-B228-4B0B736C3F3E Q33630954-6ADC504E-AA00-4925-BAFB-D011121599AC Q33695906-112E3223-E894-4336-9A56-1CAD46B16298 Q33909621-7A221E2E-8934-43CB-B6D3-E78360DEFBF9 Q34393208-4FFC02BF-0B53-4DC0-8EAE-32866A981BF0 Q34700714-0D7144C6-083D-4831-8807-8392D951967C Q35162458-C1F7732C-9334-4AD3-A368-F107E3E52AB3 Q35654081-1859BF00-6059-4511-8129-9D35BE5F5007 Q35714782-C2075779-3834-4F6E-BF55-61DEE24A52A5 Q35731376-442EFE1C-9198-4C23-96F8-1FAE1344858C Q36179524-D00BE9D1-B70D-46DF-8351-7BBEDC3042B7 Q36523796-BB3537BE-4ABA-4CE5-BC4C-7F397237FEF3 Q36548070-86F9234D-A6A0-4854-B720-5C5E6D612B69 Q36708989-EFF113EE-3296-4D39-8A87-F67243DAA1C6 Q36876853-B866F052-8768-4FC2-9C36-3756A95D87AA Q37049843-375494D8-3ED0-4C05-AE18-E19829FABB99 Q37345073-1DFAF0A8-946D-4054-BD1F-C3BD15D90011 Q37349392-5DFD5A0B-C533-450C-BBF7-81C76BA59E05 Q37395779-FD119610-78EF-4E51-AFB4-ABFFD1116632 Q37552020-7E882CCB-8A97-4147-A415-E353825E5DE6 Q38130476-C0EE98EB-F82A-463E-9684-E7B1BF3D5AFF Q38241774-C9A127BF-FE8D-4346-B5C6-CCD622E6E8B4 Q38246598-C3F06A58-4806-45DB-9FE3-F7BBD3AFB83F Q38289057-C426DBEF-AC05-43BA-B74E-70ADDD07B674 Q38540013-5833BFA0-B64C-451B-AB5C-E5C6ED140B8D Q38603384-A8084DF3-30DA-4A66-9260-9061AD43A05F Q38644826-8FA4F1A2-4FFA-49D7-A465-25A073F94382 Q38689508-D481B160-7A5D-4095-858D-6632DE74785B Q38777486-A3B67536-2A71-421F-870D-62F667427ECB Q38835771-1A5DA4D6-66CC-4643-B26E-2CF631764788 Q38859646-265DD949-0F63-47D3-87B6-64DCE3BF2952 Q38880077-7EAF0227-6AA9-4CB0-A490-A7D4A05CE762 Q39048645-AF0D0E48-DE41-4865-B929-8FB3F3F5B511 Q39100115-E8DFC27C-F4C6-47A4-A0AA-C0564E389316 Q40184243-11E40F52-D96E-461C-AD4E-88E412CCC07A Q40287451-10EBD54A-0070-44A3-B0FE-470055E7FAEB

P2860

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.

http://www.wikidata.org/entity/Q33406648

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Mayo prognostic model for WHO- ...... ponent mutations and outcomes.

@ast

Mayo prognostic model for WHO- ...... ponent mutations and outcomes.

@en

type

label

Mayo prognostic model for WHO- ...... ponent mutations and outcomes.

@ast

Mayo prognostic model for WHO- ...... ponent mutations and outcomes.

@en

prefLabel

Mayo prognostic model for WHO- ...... ponent mutations and outcomes.

@ast

Mayo prognostic model for WHO- ...... ponent mutations and outcomes.

@en

P1433

Q33406648-BB10F155-D944-4CC8-82BF-B39F76D6B18E

P1476

Q33406648-26BA7FB7-1CFB-46AF-99F4-B2D6375D702F

P2093

Q33406648-34BCA1DF-CD9B-4D79-B57C-8C8BAA8DA8BE

Q33406648-361F2375-07D0-46EC-B4C3-3D9CA97919DF

Q33406648-6C3A8568-9FFF-458B-ACED-109FED6BA9D1

Q33406648-6D333C06-CEA3-4324-862F-C593C558EC14

Q33406648-8535CBD8-B649-405D-BC23-095982F9144C

Q33406648-9734ECEB-4D19-4993-AA2B-50EECF121292

Q33406648-A3E26B18-D5C1-42AE-A283-462134F65702

Q33406648-A8BAF2B2-1DE7-4D71-ABD9-07F199D476A4

Q33406648-A94B4298-137A-43F9-9274-4A4283595037

Q33406648-AF5CAEBC-88D9-4D04-8BEA-38EB373A7184

P2860

Q33406648-0A63F96B-C2ED-4932-8221-13166FE027B6

Q33406648-153A3332-C39A-4853-BB5A-6A53C9AD668A

Q33406648-1A1B7C12-8D3E-42FD-8ED8-4222FDB1B185

Q33406648-37A4EAF8-56F0-4565-9AEF-8A3031D6F904

Q33406648-3E7381D0-DA1A-4445-B6BA-FFCD59280FCE

Q33406648-42157E5C-AC96-41C9-8707-3CE2CF78FF25

Q33406648-58DB6182-D607-47B0-B201-209FD270CEDF

Q33406648-84B5311F-FE12-49DE-9195-2865CF0E6BBF

Q33406648-87312160-037A-494A-8E81-C05F17D08E8B

Q33406648-986678F8-2CBA-4CAD-9AD1-83C230DFFB64

P2888

Q33406648-D6F45AC9-177E-4B5E-88DC-4ABD4C3FBD97

P304

Q33406648-B040875A-93EE-45E1-90F5-946A9A9D1587

P31

Q33406648-BBCC1EAC-3FEF-4290-91AB-2931F620805B

P356

Q33406648-60BC11DD-F960-431B-96F3-B66BCEF28D38

P433

Q33406648-FDC405DC-4E53-4823-9472-630875F7A42B

P478

Q33406648-7E5B03E6-A59C-4FD1-AB0F-E2B8DC775FBE

P50

Q33406648-F8383521-9739-42AF-8C67-88EBA34C50E9

P577

Q33406648-6D28899F-8405-465A-A858-3B255938B1E1

P6179

Q33406648-70E710DB-90B9-4BDC-8B32-5930365852C5

P698

Q33406648-34105CCF-549C-4EAF-8BCC-ABDFC021E2F9

P921

Q33406648-15784CA0-A248-45A0-867A-4D382142E7B1

Q33406648-961669CD-5009-4EEC-8DE7-90AE8AF8DBBC

Q33406648-DF87B505-6E88-4CFB-8231-B4A696D7B2BD

P356

P1433

P1476

Mayo prognostic model for WHO- ...... ponent mutations and outcomes.

@en

P2093

A Al-kali

http://www.w3.org/2001/XMLSchema#string

A Pardanani

http://www.w3.org/2001/XMLSchema#string

C A Hanson

http://www.w3.org/2001/XMLSchema#string

C M Finke

http://www.w3.org/2001/XMLSchema#string

E Padron

http://www.w3.org/2001/XMLSchema#string

J M Hodnefield

http://www.w3.org/2001/XMLSchema#string

M M Patnaik

http://www.w3.org/2001/XMLSchema#string

N A Ali

http://www.w3.org/2001/XMLSchema#string

R A Knudson

http://www.w3.org/2001/XMLSchema#string

R P Ketterling

http://www.w3.org/2001/XMLSchema#string

P2860

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

Frequent pathway mutations of splicing machinery in myelodysplasia

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

Revised international prognostic scoring system for myelodysplastic syndromes.

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.

SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

P2888

P304

1504-1510

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2013.88

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1038581255

http://www.w3.org/2001/XMLSchema#string

P698

23531518

http://www.w3.org/2001/XMLSchema#string

P921

Alþjóðaheilbrigðismálastofnunin